Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2021 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel

HAMPTON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel,...
December 09, 2020 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria

HAMPTON, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact...
November 30, 2020 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference

HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI...
November 09, 2020 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Presents Data from Oncology Portfolio at SITC 2020

-- Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated----Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 (GLOBE...
November 05, 2020 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Provides Corporate Update and Reports Third Quarter 2020 Results

HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020. “In the...
October 13, 2020 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria

HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized,...
September 10, 2020 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics to Present at Upcoming Healthcare Conferences

HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global Healthcare...
August 24, 2020 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors

HAMPTON, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients with...
August 06, 2020 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Provides Corporate Update and Reports Second Quarter 2020 Results

HAMPTON, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2020. The Company...
August 03, 2020 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call

HAMPTON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial...